31,538 Shares in Hims & Hers Health, Inc. $HIMS Bought by Havemeyer Place LP

Havemeyer Place LP acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,538 shares of the company’s stock, valued at approximately $1,024,000.

Several other large investors have also modified their holdings of HIMS. Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after buying an additional 2,533,271 shares during the period. Norges Bank bought a new stake in shares of Hims & Hers Health during the 4th quarter worth $62,153,000. Invesco Ltd. boosted its holdings in shares of Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after buying an additional 1,600,004 shares during the period. Clear Street Group Inc. bought a new stake in shares of Hims & Hers Health during the 3rd quarter worth $87,372,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after buying an additional 1,407,651 shares during the period. 63.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on HIMS shares. JPMorgan Chase & Co. decreased their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price objective on shares of Hims & Hers Health in a report on Tuesday, May 12th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $25.00 price objective on shares of Hims & Hers Health in a report on Tuesday, May 5th. Finally, Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.70.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $26.25 on Monday. The stock has a market cap of $6.08 billion, a P/E ratio of -291.71, a PEG ratio of 49.14 and a beta of 2.37. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a fifty day moving average price of $24.61 and a 200 day moving average price of $27.02. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.20 earnings per share. Analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Insider Activity

In related news, COO Michael Chi sold 97,289 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the transaction, the chief operating officer directly owned 407,282 shares in the company, valued at $10,055,792.58. This represents a 19.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 36,922 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the transaction, the chief financial officer owned 281,867 shares of the company’s stock, valued at approximately $7,300,355.30. The trade was a 11.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 212,807 shares of company stock worth $5,473,644. Corporate insiders own 11.76% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.